NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Nathalie Adda
Enanta Names Chief Medical Officer
Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has appointed Nathalie Adda, M.D., as senior VP and chief medical officer, responsible for clinical and regulatory affairs.
Dr. Adda is a specialist in infectious disease and has more than 15 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was chief medical officer, VP clinical development, medical and regulatory affairs, Transgene SA, where she led the oncology and infectious disease programs since 2012.
HemoShear Names President
HemoShear, a privately held discovery-stage biotechnology company, has promoted Vincent Aurentz from chief business officer to president. Mr. Aurentz is responsible for leading HemoShear’s scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities.
Mr. Aurentz, who joined HemoShear in July 2013, has more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive.
Bind Therapeutics Appoints President and CEO
Bind Therapeutics, a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, has appointed Andrew Hirsch president and CEO.
Mr. Hirsch had been serving in the role on an acting basis since March 2015.
His vision is to move the company forward using novel targeting ligands and therapeutic payloads to engineer nanomedicines that lead to meaningful improvements in patient care that is currently unachievable by other therapeutic modalities.
Mr. Nolan oversees all functions at AveXis, including clinical, regulatory, finance, operations, sales and marketing, manufacturing, and quality assurance.
Before joining AveXis, Mr. Nolan was the chief business officer at InterMune, where he led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development, and global manufacturing/supply chain.
Dr. Gary Ingenito
Catalyst Pharmaceuticals Appoints Chief Medical Officer
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, has appointed Gary Ingenito, M.D., Ph.D., as chief medical officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he is charged with overseeing all clinical development programs, medical affairs, regulatory, and other related functions.
Most recently, Dr. Ingentio served as head of regulatory affairs North America for biosimilars Boehringer-Ingelheim Pharmaceuticals.
Merz North America Promotes New Head of R&D
Merz North America, the U.S. affiliate of Merz Pharma Group, has named David Dobrowski as VP and head of North American research and development. In this role, Mr. Dobrowski is responsible for all medical, regulatory, and product safety functions for Merz in North America. He leads the planning and execution of all clinical and preclinical development programs in North America and serves as the global lead on all of Merz‘s research and development activities relating to medical dermatology.
Mr. Dobrowski joined Merz in March 2011 as director, regulatory affairs, and most recently served as VP, regulatory affairs and product safety.
MetaStat Names New President and CEO
MetaStat has named Doug Hamilton president and CEO of the company. Mr. Hamilton has consulted for the company as acting chief financial officer since August 2014.
Before joining MetaStat, a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, Mr. Hamilton served as partner at New Biology Ventures.
Mr. Hamilton takes over for Oscar Bronsther, M.D., who resigned as CEO and chief medical officer, but who retains his position as a member of the board of directors and becomes chairman of the company’s scientific and clinical advisory board.
Mr. Crooks brings to Fingerpaint experience that spans a spectrum of industries, including automotive, fashion, insurance, healthcare, technology, nonprofit, publishing and finance, among others.
Moonrocks Names Director of Integrated Strategy and U.S. Operations
Sherri Goldstein has been named director of integrated strategy and U.S. operations of Moonrocks International, a global consulting and communications organization.
In her role, Ms. Goldstein is charged with managing the U.S. Moonrocks team, and operates as a strategic liaison between the U.S. and offshore teams. She is responsible for also helping drive the strategic process to come up with innovative business solutions for clients, and bring structure to the organization by implementing procedures that optimize efficiency within the teams.
Before joining Moonrocks, she served as the director of client services at Publicis Life Brands Medicus for three years, where she was responsible for strategic stewardship, account team oversight, management and P&L of portfolio of brands, and co-leading business development efforts.
Leadership Evolution at Ogilvy CommonHealth Worldwide
Ogilvy CommonHealth Worldwide, the health behavior change specialists of Ogilvy & Mather, and a WPP company, has made two executive-level changes within management at the organization’s headquarters in Parsippany with the promotion of Amy Graham to general manager of Ogilvy CommonHealth Specialty Marketing and the appointment of Michael Zilligen as president of both Ogilvy CommonHealth Payer Marketing and Ogilvy Healthworld Payer Marketing.
Ms. Graham has been elevated from executive VP, director of client services, to general manager of Ogilvy CommonHealth Worldwide’s full-service professional advertising and promotion company focusing on high-science and specialty areas. In her new position, Ms. Graham leads all operations, strategic planning, and new business initiatives for Ogilvy CommonHealth Specialty Marketing, expanding upon the group’s therapeutic breadth and client roster.
Ms. Graham, who has been with the network’s specialty agency for two years, has more than 20 years of experience in the pharmaceutical industry.
Mr. Zilligen, who most recently held the position of president at Ogilvy CommonHealth Specialty Marketing, hands the reins over to Ms. Graham, as he assumes the top leadership role for Ogilvy CommonHealth Worldwide’s payer marketing agencies housed in New Jersey.
In his new role, Mr. Zilligen is focused on helping clients address the strategic implications associated with healthcare reform; bringing new innovations to the organization’s offering in areas such as patient access services, biosimilars, systems of care, and real world evidence; and driving continued collaboration and integration with Ogilvy CommonHealth Market Access, the network’s Connecticut-based payer group.
PulseCX Names Senior VP/Executive Creative Director
Dave Grillo has joined PulseCX, a healthcare advertising agency, as senior VP, executive creative director.
He brings 20 years of experience managing agency-of-record relationships, product launches, customer experience (CX) programs, and branding initiatives in the pharmaceutical and consumer industry.
He is responsible for leading creative strategy and vision on all client accounts and for growing creative collaboration across the company’s marketing strategy, measurement, account management, and technology teams. Mr. Grillo leads the team that ensures strategic thinking, analysis, and appropriate technologies are incorporated into the creative elements of every campaign, customer experience, and touch point that PulseCX creates and executes for its clients.
Dr. James Hyde-Dunn
Cello Health Adds to West
Cello Health welcomes James Hyde-Dunn, Ph.D., VP, business development, to its West Coast U.S. team. He brings broad experience to the healthcare agency, having worked more than a decade in brand management, market research, and scientific communications on both the client and agency sides. Most recently, Dr. Hyde-Dunn led a client service team for a market research company.
He is operating from the organization’s Burlingame, Calif., office, home of Promedica, the market research firm Cello acquired in December.
TKL Research Hires New VP of Global Business Development
TKL Research Inc., a full-service clinical research organization, has hired Jeffrey Bagshaw as VP of global business development for the clinical trials division.
Mr. Bagshaw is responsible for leading strategic corporate and business development efforts internationally.
Most recently, Mr. Bagshaw previously served as chief operating officer at Inclinix, where he was responsible for leading global operations, strategic partnership development and clinical research services.
Dr. Michael McKelvey
inVentiv Health Adds to Senior Management Team
inVentiv Health, a global provider of clinical development and comprehensive commercialization services, has appointed Michael McKelvey, Ph.D., as president, inVentiv Health Clinical Division, and executive VP, inVentiv Health.
Dr. McKelvey, a seasoned veteran within the contract research organization industry, has a strong background in clinical development, technology and the development of innovative industry strategies.
Before joining inVentiv Health, he served as executive VP and chief operating officer at Aptiv Solutions, a global clinical development services company focused on adaptive clinical trial design.
ERT Updates Executive
ERT, a global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics, and workflow solutions, has appointed Steve Nuckols executive VP and chief commercial officer.
As chief commercial officer, Mr. Nuckols is responsible for all global business development activities within ERT.
Mr. Nuckols, who brings more than 20 years of professional business acumen to ERT, was most recently VP and general manager for central region IT, at GE Healthcare. (PV)